Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.53 |
| ▸ | DRD3 | P35462 | 10/20 | 0.49 |
| ▸ | DRD4 | P21917 | 8/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439732 | 0.89 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1FAAH | |
| SCHEMBL3439982 | 0.87 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1KDM4E | |
| SCHEMBL3440195 | 0.86 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1FAAH | |
| SCHEMBL12020601 | 0.85 | DRD2 (0.47) | DRD2DRD3DRD4OPRM1KDM4E | |
| SCHEMBL13063129 | 0.84 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1FAAH | |
| SCHEMBL12914429 | 0.81 | DRD2 (0.46) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL12012102 | 0.80 | NAMPT (0.49) | ALDH1A1STS | |
| SCHEMBL12914388 | 0.79 | L3MBTL1 (0.47) | DRD2DRD3KDM4EALDH1A1TDP1 | |
| SCHEMBL12914427 | 0.78 | DRD2 (0.41) | DRD2DRD3DRD4OPRM1KDM4E | |
| SCHEMBL3440068 | 0.77 | CHRM1 (0.48) | DRD2DRD3DRD4ALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2061779-B1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| EP-2284166-B1 | Arylsulfonamides with analgetic activity | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2402329-B1 | Analgetic phenylsulphonamides | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2284166-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | DRD2 45/4885DRD3 33/4885DRD4 28/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | DRD2 25/4885DRD3 14/4885DRD4 17/4885 |
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | DRD2 1172/4885DRD3 1820/4885DRD4 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.